Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
April 22, 2024 17:31 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today...
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 06:59 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
March 06, 2024 16:20 ET
|
Generation Bio Co.
- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough...
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
February 27, 2024 06:59 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
November 29, 2023 06:59 ET
|
Generation Bio Co.
Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA)...
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
November 09, 2023 16:15 ET
|
Generation Bio Co.
- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system...
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
October 26, 2023 06:59 ET
|
Generation Bio Co.
70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle...
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
October 18, 2023 06:59 ET
|
Generation Bio Co.
– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and...
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
September 19, 2023 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...